The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms von Chand, Saswati, O'Hayer, Kevin, Blanco, Fernando F, Winter, Jordan M, Brody, Jonathan R

Volltext

Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS -Driven Sporadic Pancreatic Cancers von Nevler, Avinoam, Muller, Alexander J, Sutanto-Ward, Erika, DuHadaway, James B, Nagatomo, Kei, Londin, Eric, O'Hayer, Kevin, Cozzitorto, Joseph A, Lavu, Harish, Yeo, Theresa P, Curtis, Mark, Villatoro, Tatiana, Leiby, Benjamin E, Mandik-Nayak, Laura, Winter, Jordan M, Yeo, Charles J, Prendergast, George C, Brody, Jonathan R

Volltext

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor von Koblish, Holly K, Wu, Liangxing, Wang, Liang-Chuan S, Liu, Phillip C C, Wynn, Richard, Rios-Doria, Jonathan, Spitz, Susan, Liu, Hao, Volgina, Alla, Zolotarjova, Nina, Kapilashrami, Kanishk, Behshad, Elham, Covington, Maryanne, Yang, Yan-Ou, Li, Jingwei, Diamond, Sharon, Soloviev, Maxim, O'Hayer, Kevin, Rubin, Stephen, Kanellopoulou, Chrysi, Yang, Gengjie, Rupar, Mark, DiMatteo, Darlise, Lin, Luping, Stevens, Christina, Zhang, Yue, Thekkat, Pramod, Geschwindt, Ryan, Marando, Cindy, Yeleswaram, Swamy, Jackson, Jeff, Scherle, Peggy, Huber, Reid, Yao, Wenqing, Hollis, Gregory

Volltext

Randomized Phase 3 Trial of Ruxolitinib for COVID-19–Associated Acute Respiratory Distress Syndrome von Rein, Lindsay, Calero, Karel, Shah, Ronak, Ojielo, Charles, Hudock, Kristin M., Lodhi, Saba, Sadaka, Farid, Bellam, Shashi, Palma, Christopher, Hager, David N., Daniel, Jeannie, Schaub, Richard, O’Hayer, Kevin, Theodoropoulos, Nicole M.

Volltext

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors von Luke, Jason J., Fakih, Marwan, Schneider, Charles, Chiorean, E. Gabriela, Bendell, Johanna, Kristeleit, Rebecca, Kurzrock, Razelle, Blagden, Sarah P., Brana, Irene, Goff, Laura W., O’Hayer, Kevin, Geschwindt, Ryan, Smith, Michael, Zhou, Feng, Naing, Aung

Volltext

RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer von Zarei, Mahsa, Lal, Shruti, Vaziri-Gohar, Ali, O'Hayer, Kevin, Gunda, Venugopal, Singh, Pankaj K, Brody, Jonathan R, Winter, Jordan M

Volltext

Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both? von O'Hayer, Kevin M, Brody, Jonathan R

Volltext

Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307 von Balar, Arjun Vasant, Plimack, Elizabeth R., Grivas, Petros, Necchi, Andrea, De Santis, Maria, Pang, Lei, Keefe, Stephen Michael, O'Hayer, Kevin, Zhao, Yufan, De Wit, Ronald

Volltext

ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis von O'Hayer, Kevin M., Brady, Donita C., Counter, Christopher M.

Volltext

Acceptance and Commitment Therapy with Pancreatic Cancer: An Integrative Model of Palliative Care-A Case Report von O'Hayer, Catherine Virginia F, O'Hayer, Kevin Mitchell, Sama, Ashwin

Volltext

Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics von Ancrile, Brooke B, O'Hayer, Kevin M, Counter, Christopher M

Volltext

A Genetically Defined Normal Human Somatic Cell System to Study Ras Oncogenesis In Vivo and In Vitro von O'Hayer, Kevin M., Counter, Christopher M.

Volltext

Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells von Lim, Kian-Huat, O'Hayer, Kevin, Adam, Stacey J., Kendall, S. DiSean, Campbell, Paul M., Der, Channing J., Counter, Christopher M.

Volltext

Abstract LB-B19: Re-sensitizing Pancreatic Cancer, targeted siRNA inhibition of HuR von Schultz, Chris W., O'Hayer, Kevin, Bormes, Kathryn M., Dhir, Teena, Brown, Samantha, Nevlar, Avinoam, Chand, Saswati, Thomsett, Henry, Jiang, Wei, Bowers, Jessica, Rhodes, Kelly, Pishvaian, Michael, Getts, Robert, Brody, Jonathan

Volltext

Abstract 1961: Gaps in the armor: Targeting HuR to sensitize pancreatic cancer von Schultz, Christopher W., O'Hayer, Kevin, Dhir, Teena, Bolaji, Oloruntoba, Bormes, Kathryn M., Brown, Samantha Z., Thomsett, Henry, Chand, Saswati, Jain, Aditi, Jiang, Wei, McCarthy, Grace, Yeo, Charles J., Goetz, Austin, Nevler, Avinoam, Brody, Jonathan R., Winter, Jordan M., Preet, Ranjan, Dixon, Dan, Bowers, Jessica, Rhodes, Kelly, Getts, Robert

Volltext

529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors von Cutsem, Eric Van, Prenen, Hans, Delafontaine, Brant, Spencer, Kristen, Mitchell, Tara, Burris, Howard, Kotecki, Nuria, Kristeleit, Rebecca, Pinato, David, Sahebjam, Solmaz, Graham, Donna, Karasic, Thomas, Daniel, Jeannie, O’Hayer, Kevin, Geschwindt, Ryan, Piha-Paul, Sarina

Volltext

Abstract A101: IDO2 host genetic status influences progression and radiotherapy response in pancreatic ductal adenocarcinoma von Prendergast, George C., Nevler, Avinoam, Muller, Alexander J., Sutanto-Ward, Erika, DuHadaway, James B., Nagatomo, Kei, Londin, Eric, O'Hayer, Kevin, Cozzitorto, Joseph A., Lavu, Harish, Yeo, Theresa P., Curtis, Mark, Villatoro, Tatiana, Leiby, Benjamin E., Winter, Jordan M., Yeo, Charles J., Brody, Jonathan R.

Volltext

HER-2-Positive Ampullary Adenocarcinoma: A Case Report von O'Hayer, Kevin, Farber, John, Yeo, Charles J, Sama, Ashwin R

Volltext

JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction von O'Hayer, Kevin, Schaub, Richard L

Volltext bestellen

JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction von O'Hayer, Kevin, Schaub, Richard L

Volltext bestellen